WO2025202864 - ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER
National phase entry is expected:
Publication Number
WO/2025/202864
Publication Date
02.10.2025
International Application No.
PCT/IB2025/053085
International Filing Date
24.03.2025
Title **
[English]
ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER
[French]
INHIBITEURS D'ENT1 UTILISÉS EN COMBINAISON AVEC DES VIRUS ONCOLYTIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
Applicants **
ITEOS BELGIUM SA
Inventors
SANDERS, Theodore J.
HOUTHUYS, Erica Joke Kateligne Heleen
Priority Data
63/569,451
25.03.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6425 | |
| EPO | Filing, Examination, Granting | 149297 | |
| Japan | Filing, Examination, Granting | 5072 | |
| South Korea | Filing, Examination, Granting | 9794 | |
| USA | Filing, Examination, Granting | 76040 |
Total:
246,628
Contact Us
Abstract[English]
Disclosed herein are combinations, compositions, and kits comprising an ENT1 inhibitor and an oncolytic virus. In some embodiments, the ENT1 inhibitor is a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, or solvate thereof. Also disclosed herein are methods comprising administering an ENT1 inhibitor and an oncolytic virus as well as uses of an ENT1 inhibitor and an oncolytic virus in the manufacture of a medicament. (I)[French]
L'invention concerne des combinaisons, des compositions et des kits comprenant un inhibiteur d'ENT1 et un virus oncolytique. Dans certains modes de réalisation, l'inhibiteur d'ENT1 est un composé de formule (I) ou un sel, hydrate ou solvate pharmaceutiquement acceptable de celui-ci. L'invention concerne également des méthodes comprenant l'administration d'un inhibiteur d'ENT1 et d'un virus oncolytique ainsi que des utilisations d'un inhibiteur d'ENT1 et d'un virus oncolytique dans la fabrication d'un médicament. (I)